摘要
目的观察长春瑞滨和顺铂方案(NP方案)与紫杉醇和顺铂方案(TP方案)治疗晚期乳腺癌的疗效和不良反应。方法将65例晚期乳腺癌患者分为两组。NP方案组33例,NVB40mg/d,d1、d8;DDP25mg/m2,d1～d3。TP方案组32例,PTX135～150mg/m2,d1;DDP25mg/m2,d1～d3。结果NP方案有效率48.5%(16/33),中位缓解期6.5个月;TP方案有效率40.6%(13/32),中位缓解期7.8个月。组间疗效及缓解期差异无统计学意义,P>0.05。结论NP方案与TP方案对晚期乳腺癌疗效确切,不良反应可耐受,组间疗效差异无统计学意义,均可作为晚期乳腺癌一线方案应用。
Objective To observe the efficacy and toxicity of Paclitaxel （PTX） or Vinorelbine （NVB） combined with Cisplatin （DDP） in the treatment of advanced breast cancer. Methods Sixty - five cases of advanced breast cancer were studied, and among them, 33 patients received NP regimen （NVB ＋ DDP） ： NVB 40mg/day on days 1,8 plus DDP 25mg/m^2 from the first to the third day ,32 patients received TP regimen （PTX ＋ DDP） , PTX 135 - 150mg/m^2 on day 1 plus DDP 25mg/m^2 on days 1 - 3. Results In NP group, the response rate was 48.5% （16/33） , and in TP group, the response rate was 40.6% （13/32）. The median response duration of NP and TP groups was 6.5 and 7.8 months respectively. The efficacy and median response duration were not significantly different between the 2 groups （P 〉 0.05）. Conclusion Both PTX plus DDP and NVB plus DDP are effective to advanced breast cancer. There are no significant difference between the two groups. The two regimens can be applied to the first line chemotherapy.
出处
《医学研究杂志》
2009年第6期44-46,共3页
Journal of Medical Research
关键词
长春瑞滨
紫杉醇
顺铂
乳腺癌
Vinblastine
Paclitaxel
Cisplatin
Breast cancer
